ImmunityBio (IBRX) Reports Q3 Loss, Tops Revenue Estimates
Portfolio Pulse from
ImmunityBio (IBRX) reported a Q3 loss of $0.14 per share, which was better than the Zacks Consensus Estimate of a $0.18 loss. This is an improvement from the $0.19 loss per share reported a year ago.
November 12, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ImmunityBio reported a Q3 loss of $0.14 per share, beating the expected loss of $0.18 and showing improvement from last year's $0.19 loss.
The better-than-expected earnings report is likely to have a positive impact on IBRX's stock price in the short term. Beating estimates and showing year-over-year improvement are positive indicators for investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100